TI
ONCY

tru Independence’s Oncolytics Biotech ONCY Stock Holding History

tru Independence’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,500
Closed -$7 – 687
2020
Q2 		$7 Hold
3,500
– – ﹤0.01% 656
2020
Q1 		$5 Hold
3,500
– – ﹤0.01% 537
2019
Q4 		$5K Buy
+3,500
New +$3.95K ﹤0.01% 684

Other funds holding ONCY

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

tru Independence's ONCY Position: Q3 2020 in Review

tru Independence sold out of Oncolytics Biotech (ONCY) in Q3 2020, closing a stake of 3,500 shares — an estimated $7 sold.

tru Independence first reported a position in ONCY in Q4 2019 and held it in 3 quarters. The position peaked at $5K in Q4 2019. 36 funds tracked by Wall St. Rank hold ONCY as of Q3 2020.

  • tru Independence reported no remaining Oncolytics Biotech position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 3,500 Oncolytics Biotech shares in Q3 2020, an estimated $7.
  • tru Independence first reported a position in Oncolytics Biotech in Q4 2019 and held it in 3 quarters.
  • tru Independence's Oncolytics Biotech position peaked at $5K in Q4 2019.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.